Physical Activity Breaks for Prediabetes
(BURST2D Trial)
Trial Summary
What is the purpose of this trial?
Newly released guidelines recommend increased physical activity (PA) and reduced sedentary behaviors (SB) to improve glycemia and prevent the onset and progression of type 2 diabetes (T2D). Typically, 30-60 min bouts of PA are advocated per day. Although this approach increases PA, it does not decrease the length of the sedentary periods through the day. This is important because recent epidemiological data suggest that frequently interrupting sedentary time improves glucose control even in people who achieve the recommended levels of PA. Preliminary experimental data suggest that breaking up prolonged sedentary time by performing multiple short bouts (5 min) of PA throughout the day, may improve glycemia more than performing a single continuous bout of PA, and thereby potentially be a novel strategy to prevent T2D. The improvement in glycemia was observed even when the total amount of PA and total energy expenditure were matched, suggesting that how and when PA is performed over the day may matter more than how much PA is done. However, important gaps in knowledge remain including: (1) whether similar benefits on glucose control would be observed in adults with prediabetes, a clinically relevant population that is at high risk of developing T2D; (2) whether these effects are sustained or diluted over time, and (3) what are the mechanistic underpinnings. To address these gaps, the investigators propose to measure the acute and chronic effects of PA breaks on glucose control and the underlying mechanisms in individuals at risk of developing T2D. Sedentary men and women with prediabetes (n=66, 50% F) will be randomized to either an intervention designed to interrupt SB with 5-min bouts of brisk walking performed hourly for 9 hours/day, 5 days/week (BREAK) or a control condition consisting of 45-min of brisk walking performed as a single daily continuous bout, 5 days/week (ONE). The two 3-months interventions will be matched for total active time.
Will I have to stop taking my current medications?
You will need to stop taking any over-the-counter or prescribed medications (except oral contraceptives) for 3 days before certain study visits. The trial does not specify if you need to stop taking your medications for the entire study duration.
What data supports the effectiveness of the treatment BREAK for prediabetes?
Research shows that increasing physical activity can help prevent the progression from prediabetes to diabetes and improve heart health. Studies have found that people with higher levels of physical activity are less likely to have prediabetes, and lifestyle changes that include exercise can reduce the risk of developing type 2 diabetes.12345
Is it safe for humans to participate in physical activity breaks for prediabetes?
How does the BREAK treatment for prediabetes differ from other treatments?
The BREAK treatment is unique because it focuses on incorporating physical activity breaks into daily routines, which can help manage blood sugar levels and reduce the risk of developing type 2 diabetes. Unlike other treatments that may emphasize diet or medication, this approach specifically targets reducing sedentary behavior and increasing physical activity as a primary intervention.12346
Research Team
Audrey Bergouignan, PhD
Principal Investigator
University of Colorado, Denver
Eligibility Criteria
This trial is for sedentary adults aged 18-64 with prediabetes, defined by specific glucose levels. Participants should have a BMI of 18.5-40, be non-smokers, and not on medications that affect weight or metabolism. They must do less than 150 minutes of exercise weekly and sit for over 6 hours daily.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to either the BREAK or ONE intervention for 3 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- BREAK
- ONE
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Colorado, Denver
Lead Sponsor